
Please try another search
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad’s ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Name | Age | Since | Title |
---|---|---|---|
Andrew Arno | 66 | 2015 | Independent Chairman |
Fred R. Hirsch | - | 2021 | Member of Scientific & Medical Advisory Board |
John M. Kirkwood | - | 2021 | Member of Scientific & Medical Advisory Board |
Heinz-Josef Lenz | 65 | 2021 | Member of Scientific & Medical Advisory Board |
Robert L. Ferris | - | - | Member of Scientific & Medical Advisory Board |
Louis E. Silverman | 66 | 2022 | Independent Director |
Ignacio I. Wistuba | - | 2021 | Member of Scientific & Medical Advisory Board |
David R. Gandara | 77 | - | Member of Scientific & Medical Advisory Board |
Daniel F. Hayes | - | 2021 | Member of Scientific & Medical Advisory Board |
Joshua Riggs | 42 | 2022 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review